Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free SXTP Stock Alerts

60 Degrees Pharmaceuticals (SXTP) Competitors

60 Degrees Pharmaceuticals logo
$1.48 -0.01 (-0.67%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.48 +0.01 (+0.34%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SXTP vs. AIXC, NXTC, APLT, PASG, and CYCN

Should you buy 60 Degrees Pharmaceuticals stock or one of its competitors? MarketBeat compares 60 Degrees Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 60 Degrees Pharmaceuticals include Qualigen Therapeutics (AIXC), NextCure (NXTC), Applied Therapeutics (APLT), Passage Bio (PASG), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry.

How does 60 Degrees Pharmaceuticals compare to Qualigen Therapeutics?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

60 Degrees Pharmaceuticals presently has a consensus price target of $13.85, indicating a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Qualigen Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
Qualigen Therapeutics N/A -771.52%-79.52%

60 Degrees Pharmaceuticals has higher revenue and earnings than Qualigen Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00M3.92-$7.36M-$8.92N/A
Qualigen TherapeuticsN/AN/A-$16.97M-$6.47N/A

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 1 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Qualigen Therapeutics' score of 1.87 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Qualigen Therapeutics Very Positive

60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Summary

60 Degrees Pharmaceuticals beats Qualigen Therapeutics on 10 of the 14 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to NextCure?

NextCure (NASDAQ:NXTC) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

NextCure has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market.

42.7% of NextCure shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

60 Degrees Pharmaceuticals has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCureN/AN/A-$55.84M-$17.19N/A
60 Degrees Pharmaceuticals$1.00M3.92-$7.36M-$8.92N/A

NextCure has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat NextCure's return on equity.

Company Net Margins Return on Equity Return on Assets
NextCureN/A -186.96% -124.62%
60 Degrees Pharmaceuticals -574.91%N/A -131.48%

NextCure currently has a consensus target price of $19.00, indicating a potential upside of 348.11%. 60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, NextCure had 5 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 6 mentions for NextCure and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat NextCure's score of 0.60 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
NextCure Positive
60 Degrees Pharmaceuticals Very Positive

Summary

60 Degrees Pharmaceuticals beats NextCure on 8 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market.

Applied Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -340.84% -175.00%
60 Degrees Pharmaceuticals -574.91%N/A -131.48%

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Applied Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Applied Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Therapeutics Neutral
60 Degrees Pharmaceuticals Very Positive

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Applied Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 870.87%. 60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 835.81%. Given Applied Therapeutics' higher possible upside, equities research analysts clearly believe Applied Therapeutics is more favorable than 60 Degrees Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

60 Degrees Pharmaceuticals has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A
60 Degrees Pharmaceuticals$1.00M3.92-$7.36M-$8.92N/A

Summary

60 Degrees Pharmaceuticals beats Applied Therapeutics on 11 of the 16 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Passage Bio?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 835.81%. Passage Bio has a consensus target price of $13.25, indicating a potential upside of 168.22%. Given 60 Degrees Pharmaceuticals' higher possible upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Passage Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Passage Bio
1 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.11

Passage Bio has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Passage Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
Passage Bio N/A -150.88%-59.78%

60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 4.9% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00M3.92-$7.36M-$8.92N/A
Passage BioN/AN/A-$45.52M-$11.84N/A

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 1 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 equaled Passage Bio'saverage media sentiment score.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Passage Bio Very Positive

Summary

60 Degrees Pharmaceuticals beats Passage Bio on 7 of the 13 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Cyclerion Therapeutics?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cyclerion Therapeutics has a net margin of -170.11% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
Cyclerion Therapeutics -170.11%-62.10%-55.14%

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, suggesting a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 1 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 equaled Cyclerion Therapeutics'average media sentiment score.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Cyclerion Therapeutics Very Positive

60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Cyclerion Therapeutics has higher revenue and earnings than 60 Degrees Pharmaceuticals. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00M3.92-$7.36M-$8.92N/A
Cyclerion Therapeutics$1.99M7.60-$3.53M-$1.36N/A

Summary

Cyclerion Therapeutics beats 60 Degrees Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTP vs. The Competition

Export
Metric60 Degrees PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.94M$3.07B$6.87B$12.26B
Dividend YieldN/A2.07%2.67%9.79%
P/E Ratio-0.1720.2927.1423.64
Price / Sales3.92485.19517.0889.45
Price / CashN/A27.6250.5459.64
Price / Book-0.254.1310.286.07
Net Income-$7.36M$65.94M$3.60B$331.99M
7 Day Performance-1.99%-4.16%-1.27%-0.63%
1 Month Performance-9.76%-3.76%-0.37%-2.00%
1 Year Performance-71.76%9.94%18.30%13.62%

60 Degrees Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTP
60 Degrees Pharmaceuticals
3.4254 of 5 stars		$1.48
-0.7%		$13.85
+835.8%		-72.4%$3.94M$1.00MN/A3
AIXC
Qualigen Therapeutics
0.2468 of 5 stars		$0.80
+2.8%		N/AN/A$16.17MN/AN/A50
NXTC
NextCure
3.0367 of 5 stars		$4.40
-13.9%		$19.00
+331.8%		-16.5%$15.89MN/AN/A90
APLT
Applied Therapeutics
N/A$0.10
flat		$1.00
+870.9%		N/A$15.86M$1MN/A30
PASG
Passage Bio
4.1009 of 5 stars		$4.92
+0.2%		$13.25
+169.3%		-13.8%$15.79MN/AN/A130

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SXTP) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel